208 related articles for article (PubMed ID: 11791895)
1. The major fluvoxamine metabolite in urine is formed by CYP2D6.
Spigset O; Axelsson S; Norström A; Hägg S; Dahlqvist R
Eur J Clin Pharmacol; 2001 Nov; 57(9):653-8. PubMed ID: 11791895
[TBL] [Abstract][Full Text] [Related]
2. Low daily 10-mg and 20-mg doses of fluvoxamine inhibit the metabolism of both caffeine (cytochrome P4501A2) and omeprazole (cytochrome P4502C19).
Christensen M; Tybring G; Mihara K; Yasui-Furokori N; Carrillo JA; Ramos SI; Andersson K; Dahl ML; Bertilsson L
Clin Pharmacol Ther; 2002 Mar; 71(3):141-52. PubMed ID: 11907488
[TBL] [Abstract][Full Text] [Related]
3. Disposition of fluvoxamine in humans is determined by the polymorphic CYP2D6 and also by the CYP1A2 activity.
Carrillo JA; Dahl ML; Svensson JO; Alm C; Rodríguez I; Bertilsson L
Clin Pharmacol Ther; 1996 Aug; 60(2):183-90. PubMed ID: 8823236
[TBL] [Abstract][Full Text] [Related]
4. Non-linear fluvoxamine disposition.
Spigset O; Granberg K; Hägg S; Söderström E; Dahlqvist R
Br J Clin Pharmacol; 1998 Mar; 45(3):257-63. PubMed ID: 9517369
[TBL] [Abstract][Full Text] [Related]
5. Lack of correlation between fluvoxamine clearance and CYP1A2 activity as measured by systemic caffeine clearance.
Spigset O; Hägg S; Söderström E; Dahlqvist R
Eur J Clin Pharmacol; 1999 Feb; 54(12):943-6. PubMed ID: 10192755
[TBL] [Abstract][Full Text] [Related]
6. Determinants of interindividual variability and extent of CYP2D6 and CYP1A2 inhibition by paroxetine and fluvoxamine in vivo.
Ozdemir V; Naranjo CA; Shulman RW; Herrmann N; Sellers EM; Reed K; Kalow W
J Clin Psychopharmacol; 1998 Jun; 18(3):198-207. PubMed ID: 9617978
[TBL] [Abstract][Full Text] [Related]
7. Dose-dependent inhibition of CYP1A2, CYP2C19 and CYP2D6 by citalopram, fluoxetine, fluvoxamine and paroxetine.
Jeppesen U; Gram LF; Vistisen K; Loft S; Poulsen HE; Brøsen K
Eur J Clin Pharmacol; 1996; 51(1):73-8. PubMed ID: 8880055
[TBL] [Abstract][Full Text] [Related]
8. Fluvoxamine impairs single-dose caffeine clearance without altering caffeine pharmacodynamics.
Culm-Merdek KE; von Moltke LL; Harmatz JS; Greenblatt DJ
Br J Clin Pharmacol; 2005 Nov; 60(5):486-93. PubMed ID: 16236038
[TBL] [Abstract][Full Text] [Related]
9. CYP2D6 genotype and smoking influence fluvoxamine steady-state concentration in Japanese psychiatric patients: lessons for genotype-phenotype association study design in translational pharmacogenetics.
Suzuki Y; Sugai T; Fukui N; Watanabe J; Ono S; Inoue Y; Ozdemir V; Someya T
J Psychopharmacol; 2011 Jul; 25(7):908-14. PubMed ID: 20547595
[TBL] [Abstract][Full Text] [Related]
10. In Vivo Assessment of the Effect of CYP1A2 Inhibition and Induction on Pomalidomide Pharmacokinetics in Healthy Subjects.
Li Y; Liu L; Wang X; Zhang C; Reyes J; Hoffmann M; Palmisano M; Zhou S
J Clin Pharmacol; 2018 Oct; 58(10):1295-1304. PubMed ID: 29762875
[TBL] [Abstract][Full Text] [Related]
11. The relationship between clinical pharmacokinetics of aripiprazole and CYP2D6 genetic polymorphism: effects of CYP enzyme inhibition by coadministration of paroxetine or fluvoxamine.
Azuma J; Hasunuma T; Kubo M; Miyatake M; Koue T; Higashi K; Fujiwara T; Kitahara S; Katano T; Hara S
Eur J Clin Pharmacol; 2012 Jan; 68(1):29-37. PubMed ID: 21739267
[TBL] [Abstract][Full Text] [Related]
12. Effect of cigarette smoking on fluvoxamine pharmacokinetics in humans.
Spigset O; Carleborg L; Hedenmalm K; Dahlqvist R
Clin Pharmacol Ther; 1995 Oct; 58(4):399-403. PubMed ID: 7586931
[TBL] [Abstract][Full Text] [Related]
13. Olanzapine disposition in humans is unrelated to CYP1A2 and CYP2D6 phenotypes.
Hägg S; Spigset O; Lakso HA; Dahlqvist R
Eur J Clin Pharmacol; 2001 Sep; 57(6-7):493-7. PubMed ID: 11699614
[TBL] [Abstract][Full Text] [Related]
14. Effect of fluvoxamine therapy on the activities of CYP1A2, CYP2D6, and CYP3A as determined by phenotyping.
Kashuba AD; Nafziger AN; Kearns GL; Leeder JS; Gotschall R; Rocci ML; Kulawy RW; Beck DJ; Bertino JS
Clin Pharmacol Ther; 1998 Sep; 64(3):257-68. PubMed ID: 9757149
[TBL] [Abstract][Full Text] [Related]
15. Different effects of fluvoxamine on rabeprazole pharmacokinetics in relation to CYP2C19 genotype status.
Uno T; Shimizu M; Yasui-Furukori N; Sugawara K; Tateishi T
Br J Clin Pharmacol; 2006 Mar; 61(3):309-14. PubMed ID: 16487224
[TBL] [Abstract][Full Text] [Related]
16. Venlafaxine: in vitro inhibition of CYP2D6 dependent imipramine and desipramine metabolism; comparative studies with selected SSRIs, and effects on human hepatic CYP3A4, CYP2C9 and CYP1A2.
Ball SE; Ahern D; Scatina J; Kao J
Br J Clin Pharmacol; 1997 Jun; 43(6):619-26. PubMed ID: 9205822
[TBL] [Abstract][Full Text] [Related]
17. Dose-dependent effect of the CYP2D6 genotype on the steady-state fluvoxamine concentration.
Watanabe J; Suzuki Y; Fukui N; Sugai T; Ono S; Inoue Y; Someya T
Ther Drug Monit; 2008 Dec; 30(6):705-8. PubMed ID: 18978520
[TBL] [Abstract][Full Text] [Related]
18. Combined phenotypic assessment of CYP1A2, CYP2C19, CYP2D6, CYP3A, N-acetyltransferase-2, and xanthine oxidase with the "Cooperstown cocktail".
Streetman DS; Bleakley JF; Kim JS; Nafziger AN; Leeder JS; Gaedigk A; Gotschall R; Kearns GL; Bertino JS
Clin Pharmacol Ther; 2000 Oct; 68(4):375-83. PubMed ID: 11061577
[TBL] [Abstract][Full Text] [Related]
19. CYP2D6 and CYP2C19 activity in a large population of Dutch healthy volunteers: indications for oral contraceptive-related gender differences.
Tamminga WJ; Wemer J; Oosterhuis B; Weiling J; Wilffert B; de Leij LF; de Zeeuw RA; Jonkman JH
Eur J Clin Pharmacol; 1999 May; 55(3):177-84. PubMed ID: 10379632
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics of venlafaxine extended release 75 mg and desvenlafaxine 50 mg in healthy CYP2D6 extensive and poor metabolizers: a randomized, open-label, two-period, parallel-group, crossover study.
Nichols AI; Focht K; Jiang Q; Preskorn SH; Kane CP
Clin Drug Investig; 2011; 31(3):155-67. PubMed ID: 21288052
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
